Stock comparison
Haemonetics
Viatris
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
VTRS
Viatris
Market cap
$19.39B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | VTRS | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 31F | HAE |
| Benjamin Graham | 85A | 27F | HAE |
| Philip Fisher | 60C | 18F | HAE |
| Peter Lynch | 54C | 7F | HAE |
| Joel Greenblatt | 31F | 0F | HAE |
| Charlie Munger | 54D | 26F | HAE |
| Terry Smith | 55D | 17F | HAE |
Side-by-side metrics
| Metric | HAE | VTRS |
|---|---|---|
| Market cap | $2.98B | $19.39B |
| P/E (TTM) | 24.8x | - |
| EV/EBIT | 14.1x | - |
| ROIC (TTM) | 8.37% | 0.16% |
| Gross margin | 55.74% | 34.4% |
| Net margin | 7.29% | -2.04% |
| Revenue CAGR 5y | 7.65% | -5.44% |
| EPS CAGR 5y | 24.62% | -69.69% |
| Debt / Equity | 1.5x | 1.0x |
| Dividend yield | 0.0% | 2.8% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- Revenue CAGR 5y7.65%vs -5.44%+171%
- EPS CAGR 5y24.62%vs -69.69%+135%
- Net margin7.29%vs -2.04%+128%
- ROIC (TTM)8.37%vs 0.16%+98%
VTRS leads on
- EV/EBIT-vs 14.1x+187%
- P/E (TTM)-vs 24.8x+137%
- Dividend yield2.8%vs 0.0%+100%
- Market cap$19.39Bvs $2.98B+85%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.